Saturday 17 October 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024. In the quarter to June 2026, revenue grew 296.1%, EPS grew 96.5%, free cash flow grew 54.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
96.27
2.94
−2.96%
Follow INSM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 4 | 5 | 5 |
| (165.69%) | (249.28%) | (294.46%) | (87.22%) | ||
| (53.64%) | (59.53%) | (61.04%) | (38.20%) | ||
ROIC |
0.00% | 0.00% | (1,659.95%) | (329.22%) | |
Return on Tangible Assets |
(73.79%) | (89.39%) | (87.36%) | (67.21%) | |
Average Days of Receivables |
53.28 | 84.78 | 79.52 | 69.09 | |
Free Cash Flow per Share |
(4.28) | (4.86) | (4.28) | (3.72) | |
Free Cash Flow |
(906.14) | (967.57) | (921.63) | (807.67) | |
Capital Expenditures |
(22.74) | (32.56) | (25.97) | (28.75) | |
| Other line items | |||||
Cash ROIC |
(28.43%) | (35.43%) | (37.01%) | (32.56%) | |
Accounts Receivable Turnover |
8.31 | 6.29 | 7.24 | 8.42 | |
Accounts Payable Turnover |
0.32 | 0.33 | 0.51 | 0.51 | |
Inventory Turnover |
0.96 | 1.07 | 1.28 | 1.51 | |
Average Days of Payables |
1,426.44 | 1,354.03 | 863.18 | 831.80 | |
Days of Inventory on Hand |
421.02 | 392.11 | 325.41 | 276.12 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
155.68% | 127.15% | 101.03% | 75.67% | |
Selling, General and Administrative Expense of Revenue |
141.20% | 115.62% | 97.72% | 78.55% | |
Share Based Compensation of Revenue |
31.37% | 25.18% | 19.43% | 13.84% | |
Interest Coverage |
(13.66) | (14.88) | (14.00) | (10.34) | |
Operating CF/Net income |
0.75 | 0.73 | 0.76 | 0.89 | |
Depreciation/Fixed assets |
0.26 | 0.25 | 0.26 | 0.26 | |
Capex/Depreciation |
(0.99) | (1.28) | (0.97) | (1.02) | |
Revenue per Share |
2.11 | 3.05 | 3.80 | 5.23 | |
Operating CF per Share |
(4.17) | (4.70) | (4.16) | (3.58) | |
Capex per Share |
(0.11) | (0.16) | (0.12) | (0.13) | |
Capex to Sales |
0.05 | 0.05 | 0.03 | 0.03 |
Columns are period end dates